Treadwell Therapeutics is an oncology company in the clinical development phase that is capitalizing on the weaknesses of cancer cells to create unique and top-notch small molecules to meet the needs of cancer patients. Leveraging distinctive innovations from our founders, collaborators, and the highly skilled scientists at TIO Discovery, we are progressing a series of innovative clinical candidates with the potential to target genomic instability across various cancers and previously unexplored immuno-oncology objectives.